The three recommended steps:
- Apply Ocular Light Therapy While Protecting the Macula
- Utilize Myopia Control Lenses in Combination
- Continue with Myopia Control Lenses To Prevent Rebound
The Proof!
Low-Level Red-Light Therapy While Protecting the Macula Increases Myopia Control Response
2025 | pmc.ncbi.nlm.nih.gov
100% Stoppage of Myopia Progression with Low-Level Red-Light Therapy and Myopia Control Lenses
2025 | nature.com
2025 | sciencedirect.com
The need for Macula Protection with Ocular Light Therapy
2024| modernretina.com
Reduction of Cone Density – Shows Need for Myopia Protection with Ocular Light Therapy
2025 | jamanetwork.com
Zero Myopia Rebound with Myopia Control Lenses
2024 | onlinelibrary.wiley.com
The Next Visual is for Ophthalmic Therapy Companies, Equipment Manufacturers, Eye Care Professionals (ECPs), Neuro-Scientists; To Imagine the Various Potential Applications for Treating Eye and Neurological Disorders with Ocular Light Therapy Safely in Office or Home.
The Next Visual is for Ophthalmic Therapy Companies, Equipment Manufacturers, Eye Care Professionals (ECPs), Neuro-Scientists; To Imagine the Various Potential Applications for Treating Eye and Neurological Disorders with Ocular Light Therapy Safely in Office or Home.
Ocular Light Therapy – Safety, Efficacy, & Speed
System Flexibility Providing Numerous Additional Opportunities
- Radiate Most of Retina with Appropriate Light Wavelengths (Blue, Cyan, Red), Intensity & Time
- Protect the Entire Macula While Radiating Peripheral Retina
- Protect the Fovea, Radiate the Remainer of the Macula and Peripheral Retina
- Protect the Fovea, Radiate the Remainer of the Macula
- Protect the Fovea, Radiate the Parafovea (Highest Density of ipRGCs)
- Protect the Macula, Radiate circular band around Macula (Highest Density of Rods)
- Protect the Fovea and Parafovea, Radiate the Perifovea
- Protect the Fovea, Radiate Macula, Increase Radiation Intensity of Peripheral Retina
- Radiate Large Areas of Peripheral Retina while Protecting Macula
- Radiate Peripheral Retina while Radiating the Macula with Less Radiation
NeuroRays™ Holds the Key to Safely Treating 1 Billion Myopes Ages 6yrs – 23yrs
NeuroRays™ Intellectual Property (Method, Device, System) Protects Each Step Needed to Safely Stop Myopia Progression without Rebound
NeuroRays is Having Discussions with Potential Partners. Contact:
Ron Blum OD, DOS of NeuroRays
Rblum@EggFactory.com
– OR –
Udit Patel of Piper Sandler /
Udit.Patel@psc.com / PiperSandler.com